Eduovisual
Respiratory
COPD: GOLD-based outpatient pharmacotherapy
— Adult ≥40 with dyspnea on exertion, chronic cough (>3 months/year × 2 years for chronic bronchitis), or recurrent lower respiratory infections
— Exposure history: ≥10 pack-year tobacco use, occupational dusts/fumes (mining, welding, textiles), biomass smoke (developing countries, indoor cooking), prior TB, childhood respiratory infection
— Family history of alpha-1 antitrypsin deficiency (test all symptomatic COPD patients once, especially if <45 yo, lower-lobe emphysema, or nonsmoker)
— GOLD 1–4 grades severity by post-bronchodilator FEV1 (≥80, 50–79, 30–49, <30% predicted)
— GOLD groups A, B, E stratify by symptoms (mMRC/CAT) and exacerbation history → drive pharmacotherapy initiation
— Note: GOLD 2023 collapsed prior C/D into a single high-exacerbator group E
Board pearl: A 55-year-old smoker with chronic productive cough and FEV1/FVC 0.65 post-bronchodilator has COPD — even if FEV1 is 85% predicted. The ratio defines disease; FEV1 grades severity. Don't be fooled by "normal" FEV1 when the ratio is fixed and obstructive.
Step 3 management: Always confirm with post-bronchodilator spirometry before labeling and treating; empiric inhaler trials without PFTs is a classic distractor wrong answer.
— Dyspnea: progressive, persistent, worse with exertion — the most predictive symptom
— Chronic cough: may be intermittent, often productive but can be dry
— Sputum production: chronic mucus hypersecretion suggests bronchitic phenotype
— mMRC (Modified Medical Research Council) dyspnea scale 0–4: 0 = only with strenuous exercise; 2 = walks slower than peers or stops for breath on level ground; 4 = too breathless to leave house
— CAT (COPD Assessment Test): 8-item, score 0–40; CAT ≥10 = high symptom burden
— Thresholds defining "more symptoms": mMRC ≥2 OR CAT ≥10
— ≥2 moderate exacerbations/year, OR ≥1 leading to hospitalization → high-risk
— Ask specifically: "How many courses of prednisone or antibiotics for breathing in the past year? Any ER visits or admissions?"
— "Pink puffer" (emphysema-predominant): thin, pursed-lip breathing, minimal sputum, severe dyspnea, hyperinflation
— "Blue bloater" (chronic bronchitis): overweight, cyanosis, copious sputum, cor pulmonale, more hypoxemia
— Most patients are mixed; phenotype labels are de-emphasized clinically but still tested
— Pack-years (cigarettes/day × years/20); current vs. former smoker
— Occupational/environmental exposures, biomass fuel
— AAT deficiency screen indication: all symptomatic COPD patients per ATS/ERS, especially <45 yo, basilar emphysema, family history, or nonsmoker with COPD
— Comorbidities driving outcomes: CV disease, lung cancer, anxiety/depression, OSA (overlap syndrome), osteoporosis
Key distinction: Asthma typically begins in childhood with variable, reversible obstruction and atopic features. COPD presents after 40 with persistent, less reversible obstruction and exposure history. Both can coexist (asthma-COPD overlap), but classification still requires post-BD spirometry.
Board pearl: A nonsmoking 38-year-old with basilar emphysema and elevated LFTs → check alpha-1 antitrypsin level and phenotype (PiZZ) before chalking it up to idiopathic disease.
— Cachexia, accessory muscle use, pursed-lip breathing, tripod positioning
— Prolonged expiratory phase (>4 sec is abnormal)
— Central cyanosis in advanced disease (SpO2 <88%)
— Barrel chest (increased AP diameter) from hyperinflation
— Hyperresonance to percussion; decreased diaphragmatic excursion
— Decreased breath sounds (best single finding for airflow obstruction)
— End-expiratory wheeze, rhonchi, distant heart sounds
— Hoover's sign: paradoxical inward movement of lower rib cage on inspiration → severe hyperinflation
— Loud P2, RV heave, tricuspid regurgitation murmur → pulmonary hypertension/cor pulmonale
— JVD, hepatomegaly, pulsatile liver, peripheral edema → right heart failure
— Tachycardia common; multifocal atrial tachycardia is classic COPD arrhythmia
— Digital clubbing is NOT typical of COPD — if present, evaluate for lung cancer, bronchiectasis, or ILD
— Asterixis suggests CO2 retention (hypercapnia)
— Pulsus paradoxus >10 mmHg (severe air trapping)
— Hypotension during exacerbation may indicate tension pneumothorax (bleb rupture), sepsis, or auto-PEEP physiology
— SpO2 — target 88–92% in known/suspected COPD (avoid overshoot)
— Resting SpO2 (ambulatory; assess with 6-minute walk if borderline)
— BMI (low BMI portends worse mortality — part of BODE index)
— Resting HR, BP
Key distinction: Clubbing in a "COPD patient" should always prompt workup for bronchogenic carcinoma, especially given shared smoking risk. Do not attribute clubbing to COPD itself.
Board pearl: Hoover's sign + barrel chest + pursed-lip breathing in a smoker = severe emphysema with hyperinflation; expect low DLCO and consider lung volume reduction evaluation if FEV1 <50% with upper-lobe predominance and poor exercise tolerance.
— Administer short-acting bronchodilator (albuterol), repeat in 10–15 min
— Post-bronchodilator FEV1/FVC < 0.70 confirms persistent airflow obstruction
— Grade severity by FEV1 % predicted:
– GOLD 1 (mild): FEV1 ≥80%
– GOLD 2 (moderate): 50–79%
– GOLD 3 (severe): 30–49%
– GOLD 4 (very severe): <30%
— Reversibility (Δ FEV1 ≥12% AND ≥200 mL) suggests asthma component but does NOT exclude COPD
— CXR: hyperinflation (>10 posterior ribs), flattened diaphragms, increased retrosternal airspace, narrow cardiac silhouette, bullae. Insensitive but useful to exclude alternatives.
— HRCT chest: not routine for diagnosis; obtain if considering lung cancer screening (annual LDCT for ages 50–80, ≥20 pack-years, current/quit <15 yr), surgical evaluation, or atypical features (bronchiectasis, ILD suspicion)
— CBC: polycythemia (chronic hypoxia) or anemia (worsens dyspnea, treatable)
— BMP: baseline renal function before diuretics/inhalers
— Alpha-1 antitrypsin level — once in every symptomatic COPD patient (ATS/ERS, GOLD)
— BNP, troponin if exacerbation with diagnostic ambiguity (HF overlap)
— Resting SpO2 at every visit; ABG if SpO2 ≤92%, suspected hypercapnia, or pre-LTOT evaluation
— Right axis deviation, P pulmonale (peaked P >2.5 mm in II), RVH, multifocal atrial tachycardia
Step 3 management: Don't order spirometry during an acute exacerbation — results are unreliable. Wait 4–6 weeks post-exacerbation for diagnostic confirmation in newly suspected COPD.
Board pearl: The single most cost-effective and diagnostic test for new dyspnea in a smoker over 40 is post-bronchodilator spirometry, not CT or BNP.
— Lung volumes (body plethysmography): ↑ TLC, ↑ RV, ↑ FRC, ↑ RV/TLC ratio = hyperinflation/air trapping
— DLCO: reduced in emphysema (destruction of alveolar-capillary interface); normal in chronic bronchitis or asthma — a key differentiator
— Obtain when phenotyping unclear, considering surgical interventions, or assessing dyspnea out of proportion to FEV1
— Indicated if FEV1 <40%, SpO2 ≤92%, suspected hypercapnia/somnolence, or evaluating for LTOT
— Chronic respiratory acidosis with compensatory ↑ HCO3; PaO2 ≤55 or SaO2 ≤88% qualifies for LTOT
— Assesses exercise capacity, oxygen desaturation with exertion (exertional LTOT criteria)
— Component of BODE index (BMI, Obstruction [FEV1], Dyspnea [mMRC], Exercise [6MWT]) — prognostic
— Serum AAT level + phenotype (PiMM normal, PiMZ heterozygote, PiZZ severe deficiency)
— If deficient: augmentation therapy (IV pooled human AAT) for PiZZ with FEV1 30–65%
— Bronchiectasis suspicion (recurrent infections, copious purulent sputum)
— Surgical candidacy: lung volume reduction surgery (upper-lobe predominant, low exercise tolerance) or bullectomy
— Lung transplant evaluation
— Concurrent lung cancer screening
— Blood eosinophils ≥300 cells/μL predict ICS responsiveness and guide GOLD group E therapy (favor LABA/LAMA/ICS triple)
— Eosinophils <100 predict poor ICS benefit and ↑ pneumonia risk → avoid ICS
Key distinction: Low DLCO with obstruction = emphysema. Normal or high DLCO with obstruction = asthma. Low DLCO with restriction = ILD. This triad shows up repeatedly.
Board pearl: Eosinophil-guided therapy is now central to GOLD: eos ≥300 → add ICS to dual bronchodilator; eos <100 → avoid ICS due to pneumonia risk and lack of benefit.
— Combines symptom burden (mMRC, CAT) with exacerbation history over the past 12 months
— Low risk: 0 or 1 moderate exacerbation, no hospitalization
— High risk (Group E): ≥2 moderate exacerbations OR ≥1 leading to hospitalization
— Low symptoms: mMRC 0–1 AND CAT <10 → Group A
— High symptoms: mMRC ≥2 OR CAT ≥10 → Group B
— Group A: low symptoms, low exacerbations → single bronchodilator (LAMA or LABA)
— Group B: high symptoms, low exacerbations → LABA + LAMA combination
— Group E: high exacerbation risk (regardless of symptoms) → LABA + LAMA; add ICS if blood eosinophils ≥300 or concurrent asthma features
— Smoking status (every visit — most important intervention)
— Comorbidities (CV disease drives mortality more than FEV1)
— Vaccination status, oxygenation, BMI, exercise capacity
Step 3 management: Before prescribing inhalers, walk through this algorithm explicitly. A common stem: "65 yo, FEV1 45%, mMRC 3, two ER visits last year for COPD." → Group E, high symptoms — start LABA + LAMA; check eosinophils to decide on ICS.
Board pearl: GOLD group dictates initial pharmacotherapy; GOLD grade (1–4) describes severity and prognosis. Mixing these up is a classic test trap. The same patient can be GOLD 3 + Group B, or GOLD 2 + Group E.
Key distinction: Symptoms (mMRC/CAT) and exacerbations are independent axes; high exacerbation history overrides symptom level for group E classification.
— SABA (albuterol) / SAMA (ipratropium): rescue only, PRN
— LABA (salmeterol, formoterol, olodaterol, indacaterol, vilanterol)
— LAMA (tiotropium, umeclidinium, glycopyrrolate, aclidinium) — first-choice maintenance for most patients
— ICS (fluticasone, budesonide, mometasone) — combine with LABA, never as monotherapy in COPD
— Roflumilast (PDE4 inhibitor): severe COPD with chronic bronchitis, FEV1 <50%, frequent exacerbations
— Azithromycin 250 mg daily or 500 mg 3×/week: former smokers with frequent exacerbations despite optimal inhalers
— Group A: LAMA (preferred) or LABA monotherapy; +SABA PRN rescue
— Group B: LABA + LAMA combination (e.g., umeclidinium/vilanterol, tiotropium/olodaterol)
— Group E:
– LABA + LAMA baseline
– Add ICS → triple therapy (LABA/LAMA/ICS) if blood eos ≥300, history of asthma, or ≥2 exacerbations/yr on dual therapy
– Examples of triple inhalers: fluticasone/umeclidinium/vilanterol, budesonide/glycopyrrolate/formoterol
— Dyspnea persists on LAMA → add LABA
— Exacerbations on LABA+LAMA + eos ≥100 → add ICS
— Exacerbations on triple therapy → add roflumilast (chronic bronchitis phenotype, FEV1 <50%) or azithromycin (former smokers)
Step 3 management: Never prescribe ICS monotherapy in COPD (unlike asthma) — increases pneumonia risk without benefit. Always pair with LABA ± LAMA.
Board pearl: Blood eosinophil count is the most important biomarker for ICS decisions: ≥300 = favor ICS; <100 = avoid ICS due to pneumonia risk.
— Varenicline (most effective monotherapy): start 1 week before quit date, titrate to 1 mg BID × 12 weeks; monitor for neuropsychiatric symptoms (boxed warning removed 2016)
— Bupropion SR 150 mg BID × 7–12 weeks; avoid in seizure disorder, eating disorders
— Nicotine replacement (patch + gum/lozenge combination) — patch for baseline craving, short-acting for breakthrough
— Combination NRT or varenicline + NRT superior to monotherapy
— Behavioral counseling at every visit (5 A's: Ask, Advise, Assess, Assist, Arrange)
— 500 μg PO daily; reduces exacerbations in severe COPD with chronic bronchitis phenotype
— AE: weight loss, nausea, diarrhea, depression/suicidality, headache — counsel and monitor
— Contraindicated in moderate-severe hepatic impairment
— 250 mg daily or 500 mg 3×/wk reduces exacerbations
— Pre-Rx: baseline EKG (QTc), LFTs, hearing assessment; screen for NTM
— Avoid if QTc >450 ms, on other QT-prolonging drugs, or current smoker (less benefit)
— N-acetylcysteine or carbocysteine may reduce exacerbations modestly in chronic bronchitis; not first-line
— Indications: resting PaO2 ≤55 mmHg or SaO2 ≤88%; or PaO2 56–59 with cor pulmonale, polycythemia (Hct >55), or right heart failure
— Goal: ≥15 hours/day to confer survival benefit
CCS pearl: On a CCS case of stable COPD, the highest-yield orders are: smoking cessation counseling, pneumococcal + influenza + RSV + COVID vaccines, pulmonary rehab referral, inhaler technique review.
— Inhaler technique is the biggest pitfall — assess at every visit; up to 50% misuse devices
— Prefer soft-mist inhalers (Respimat) or DPIs with low inspiratory flow requirements if weak inspiration; avoid MDIs without spacer
— Cognitive impairment + complex regimens → consider single-inhaler triple therapy to simplify
— Polypharmacy: review for anticholinergic burden when adding LAMA (urinary retention, dry mouth, constipation, cognitive effects)
— Beta-blocker concerns: cardioselective β1-blockers (metoprolol, bisoprolol) are SAFE and recommended in COPD + CV disease; do not withhold for COPD alone
— Acute angle-closure glaucoma — avoid eye contact, screen for narrow angles
— BPH/urinary retention — counsel; consider alternative
— Tiotropium has favorable safety in long-term trials
— Most inhaled drugs minimally renally cleared — no dose adjustment for LABA, LAMA, ICS
— Glycopyrrolate has some renal clearance; use cautiously if CrCl <30
— Roflumilast: no renal dose adjustment, but limited data <30
— Avoid theophylline if CKD due to narrow therapeutic index
— Roflumilast contraindicated in moderate-severe hepatic impairment (Child-Pugh B/C)
— Fluticasone and budesonide undergo hepatic metabolism; in severe hepatic disease, exposure ↑
— Theophylline metabolized by CYP1A2 — markedly reduced clearance in liver disease, multiple drug interactions
— Annual influenza
— PCV20 (or PCV15 + PPSV23) per ACIP
— RSV vaccine for adults ≥60 with chronic lung disease
— COVID-19 boosters
— Tdap, zoster age-appropriate
Step 3 management: Cardioselective beta-blockers (metoprolol succinate, bisoprolol) should not be withheld in a COPD patient with HFrEF or post-MI — withholding them increases mortality more than any bronchospasm risk.
Board pearl: A confused 78-year-old on tiotropium with urinary retention and dry mouth → consider anticholinergic toxicity; switch to LABA-predominant regimen.
— COPD itself is rare in reproductive age unless alpha-1 antitrypsin deficiency or severe early-onset disease
— Smoking cessation is paramount — nicotine replacement preferred over varenicline/bupropion in pregnancy (limited safety data, but NRT is favored when behavioral fails)
— Inhaled bronchodilators (SABA, LABA, LAMA) and ICS are generally considered safe; benefits of disease control outweigh theoretical risks (asthma data extrapolated)
— Avoid roflumilast (limited data) and azithromycin chronic prophylaxis (uncertain pregnancy data)
— Hypoxemia harms fetus — maintain maternal SpO2 ≥95% during exacerbations
— Suspect in nonsmokers, <45 yo, basilar emphysema, family history, unexplained liver disease
— Test AAT serum level + phenotyping (Pi typing); PiZZ is severe
— IV augmentation therapy (pooled human AAT, weekly) for PiZZ + FEV1 30–65%
— Counsel about hepatic involvement; screen with LFTs and liver imaging
— Family screening recommended
— Fixed obstruction + features of asthma (atopy, reversibility, eosinophilia, childhood symptoms)
— Start with ICS-containing regimen (ICS/LABA or triple), unlike pure COPD where ICS is conditional
— Worse nocturnal hypoxemia, pulmonary HTN, mortality
— CPAP improves survival; screen with home sleep study or polysomnography if BMI elevated, snoring, witnessed apneas
Key distinction: A 40-year-old nonsmoker with basilar bullae and elevated AST/ALT → AAT deficiency until proven otherwise. Classic COPD has upper-lobe predominance in smokers; AAT deficiency causes lower-lobe emphysema due to lack of antiprotease activity where neutrophil density is highest.
Board pearl: Always screen for OSA in obese COPD patients with morning headaches or refractory pulmonary hypertension — treating OSA dramatically improves outcomes.
— Most common complication; defined by acute worsening of dyspnea, cough, or sputum (volume/purulence) beyond daily variation
— Anthonisen criteria for antibiotics: ↑ dyspnea + ↑ sputum volume + ↑ sputum purulence (2 of 3, especially with purulence)
— Triggers: viral URI (>50%), bacterial (H. influenzae, S. pneumoniae, M. catarrhalis, Pseudomonas in severe), air pollution, nonadherence
— Chronic hypoxemia → hypoxic pulmonary vasoconstriction → pulmonary HTN → RV hypertrophy/failure
— LTOT is the only therapy proven to reduce mortality in hypoxemic COPD and slows pulmonary HTN progression
— Avoid PAH-specific therapies in COPD-related pulmonary HTN (may worsen V/Q mismatch)
— Type I (hypoxemic): V/Q mismatch
— Type II (hypercapnic): inadequate ventilation, CO2 retention; chronic compensated picture vs. acute decompensation
CCS pearl: For inpatient AECOPD admission, standing orders should include: controlled O2 to SpO2 88–92%, nebulized SABA + SAMA, systemic corticosteroids (prednisone 40 mg × 5 days), antibiotics if Anthonisen criteria met, VTE prophylaxis, early NIV if pH <7.35 and PaCO2 >45.
Board pearl: Sudden unilateral dyspnea + chest pain in a known COPD patient with bullae = pneumothorax — get an upright CXR immediately.
— Manage at home: mild dyspnea, no comorbid concerns, good support, baseline function
— Refer to ED: severe dyspnea at rest, SpO2 <90% on home O2 (or new hypoxemia), altered mentation, hemodynamic instability, failed outpatient therapy after 48–72 hr, severe comorbidities (HF, CKD, age >65 with frailty)
— Inability to walk between rooms / eat / sleep due to dyspnea
— Worsening hypoxemia or hypercapnia
— New cyanosis, peripheral edema
— Failure to respond to ED treatment
— Inadequate home support
— Severe dyspnea inadequately responding to initial emergency therapy
— Change in mental status (confusion, lethargy, coma)
— Persistent or worsening hypoxemia (PaO2 <40) or severe/worsening respiratory acidosis (pH <7.25) despite supplemental O2 and NIV
— Need for invasive mechanical ventilation
— Hemodynamic instability requiring vasopressors
— Indications: acute respiratory acidosis (pH ≤7.35, PaCO2 ≥45), severe dyspnea with accessory muscle use/paradoxical abdominal motion, persistent hypoxemia despite O2
— Contraindications: impaired consciousness (relative), facial trauma, copious secretions, hemodynamic instability, recent upper GI surgery
— NIV reduces intubation, mortality, and length of stay — strongest evidence base
— NIV failure or intolerance
— Cardiopulmonary arrest, severe hemodynamic instability
— Decreased consciousness with inability to protect airway
— Persistent inability to clear secretions
— Diagnostic uncertainty, age <40, AAT deficiency
— Rapid FEV1 decline, frequent exacerbations despite triple therapy
— Evaluation for surgical interventions, transplant, LTOT initiation
— Severe disease (GOLD 3–4)
Step 3 management: A COPD patient in the ED with pH 7.28, PaCO2 68, RR 32, accessory muscle use → start BiPAP immediately; if no improvement in 1–2 hours or worsening mentation, intubate. Do not delay NIV waiting for ABG trends.
— Onset usually <40, often childhood; episodic, reversible obstruction (≥12% and ≥200 mL ↑ FEV1 post-BD)
— Atopic features: eczema, allergic rhinitis, eosinophilia, elevated IgE
— Triggers: allergens, cold air, exercise
— DLCO normal or elevated; ICS is first-line (opposite of COPD)
— Symptoms vary day-to-day; nocturnal symptoms common
— Features of both: chronic obstruction + significant reversibility/eosinophilia or asthma history
— Treat as asthma with COPD overlay → ICS-containing regimen first
— Chronic productive cough with large-volume purulent sputum, recurrent infections
— HRCT: dilated bronchi, "signet ring" sign, tram tracks, lack of tapering
— Causes: post-infectious (TB, severe pneumonia), CF, immunodeficiencies, ABPA, NTM
— Treat: airway clearance, targeted antibiotics; chronic macrolides if frequent exacerbations
— Younger patients, family history, GI/pancreatic involvement, infertility (males), nasal polyps
— Sweat chloride ≥60 mmol/L diagnostic; CFTR genetic testing
— Now consider CFTR modulators (elexacaftor/tezacaftor/ivacaftor)
— Post-transplant (lung, HSCT), post-inhalation injury (popcorn workers, diacetyl), connective tissue disease
— Fixed obstruction, mosaic attenuation on expiratory CT
— Tracheal stenosis (post-intubation), tumors, vocal cord dysfunction
— Flow-volume loop shows flattening of inspiratory/expiratory limbs (different patterns localize lesion)
— Asthma + eosinophilia + vasculitis; ANCA-positive in subset
Key distinction: Asthma is reversible, episodic, allergic-driven, with normal/high DLCO. COPD is persistent, progressive, exposure-driven, with often low DLCO in emphysema. Reversibility on PFTs does NOT exclude COPD.
Board pearl: Chronic large-volume purulent sputum + recurrent infections + finger clubbing → bronchiectasis, not COPD. Get HRCT.
— Orthopnea, PND, peripheral edema, S3 gallop
— BNP/NT-proBNP elevated (BNP >100, NT-proBNP >300–900 depending on age)
— Echocardiogram diagnostic
— Frequent COPD comorbidity — both may coexist; diuresis + cardioselective β-blocker improves both
— Velcro crackles, clubbing, restrictive pattern on PFTs (low TLC, normal FEV1/FVC)
— Low DLCO common to both ILD and emphysema — distinguish by lung volumes
— HRCT: reticulation, honeycombing, ground glass
— Idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, CTD-ILD
— Acute or subacute dyspnea, pleuritic pain, hemoptysis, tachycardia
— D-dimer, CTPA; consider in any COPD patient with disproportionate dyspnea or hypoxemia
— PE causes ~25% of "unexplained" COPD exacerbations — have a low threshold
— Progressive exertional dyspnea, exertional syncope, loud P2, RV heave
— Echo screen → RHC confirmation
Step 3 management: A 70-year-old smoker with dyspnea, leg edema, and basilar crackles — don't reflexively label as "COPD exacerbation." Get BNP, echo, CXR; HFpEF mimics COPD frequently and benefits from very different therapy (diuresis, BP control, SGLT2 inhibitors).
Board pearl: When a "COPD exacerbation" doesn't improve as expected on standard therapy → think PE, HF, or pneumothorax before escalating bronchodilators.
— Address at every visit; combine pharmacotherapy + behavioral counseling
— Cessation slows FEV1 decline and reduces mortality more than any drug
— Annual influenza (preferred standard or high-dose ≥65)
— Pneumococcal: PCV20 alone, OR PCV15 followed by PPSV23 ≥1 year later (ACIP 2022)
— RSV for adults ≥60 with chronic lung disease (shared decision-making)
— COVID-19 boosters per current schedule
— Tdap every 10 years; zoster ≥50
— Complete prednisone 40 mg × 5 days (no taper needed)
— Antibiotics × 5 days if indicated (azithromycin, doxycycline, or amox-clav)
— Resume/initiate maintenance LABA/LAMA ± ICS per GOLD group
— Albuterol PRN rescue
— Inhaler technique review before discharge and at first follow-up
— Action plan with written instructions for symptom recognition and self-management
— Refer within 4 weeks of exacerbation discharge — reduces readmission and mortality
— Indicated for mMRC ≥2 or significant functional limitation
— Statin for ASCVD per guidelines
— Aspirin for secondary CV prevention
— DEXA scan; calcium/vitamin D, bisphosphonate if osteoporotic
— Screen and treat depression/anxiety
— Annual LDCT lung cancer screening if eligible
— Begin discussions in moderate-severe disease; document goals of care, code status, palliative care referral when appropriate
CCS pearl: Discharge order set after AECOPD admission: prednisone (finish course), maintenance inhaler, rescue albuterol, oxygen if criteria met, pulmonary rehab referral, smoking cessation referral/Rx, follow-up in 1–4 weeks, written action plan, vaccinate before discharge.
Board pearl: A post-AECOPD patient referred to pulm rehab within 4 weeks has lower 90-day readmission and mortality — a high-yield Step 3 question stem.
— Post-exacerbation: within 1–4 weeks (review symptoms, inhaler technique, adherence, escalate therapy if needed; consider spirometry at 6–8 weeks if diagnosis unclear)
— Stable mild COPD: every 6–12 months
— Moderate-severe: every 3–6 months
— More frequent during initial titration or after therapy change
— Symptom burden: mMRC, CAT score
— Exacerbation count since last visit
— Smoking status; reinforce cessation
— Inhaler technique (have patient demonstrate — top cause of treatment failure)
— Adherence (PDC, refill records)
— SpO2 (resting; ambulatory if borderline)
— BMI, depression screen, sleep symptoms
— Vaccinations up to date
— Annually in established COPD to track FEV1 decline (~30 mL/yr normal aging; >60 mL/yr accelerated)
— Repeat after therapy change in selected patients
— Reassess oxygen need 60–90 days after initiation (chronic stable state) — many no longer qualify
— Annual reassessment thereafter
— Action plan: recognize early exacerbation (↑ dyspnea, sputum change, color change → start rescue inhaler, contact clinician; written instructions for prednisone/abx if appropriate)
— Inhaler technique with spacer for MDIs; demonstrate at every visit
— Activity: encourage exercise; pulmonary rehab; energy conservation
— Nutrition: avoid low BMI; protein-rich diet
— Avoid triggers: secondhand smoke, air pollution, occupational exposures
— Travel: assess hypoxia with flight simulation if SpO2 ≤92%; oxygen orders for flights
— Opioids for refractory dyspnea in advanced disease
— Hospice eligibility: FEV1 <30%, frequent ER visits, weight loss, dependence, hypercapnia
Step 3 management: Schedule post-exacerbation follow-up within 1–4 weeks — this is a frequently tested transition-of-care quality metric and reduces readmissions.
Board pearl: Poor inhaler technique is responsible for up to 50% of "treatment failures." Always have the patient demonstrate, not describe.
— Document 5 A's at each visit; failing to counsel may be a quality measure miss
— Nonjudgmental, motivational interviewing approach; respect autonomy
— Pregnant patients: counsel about fetal harm but respect choices; offer NRT
— Initiate early in moderate-severe COPD — many patients face acute respiratory failure with no documented wishes
— Discuss intubation vs. NIV-only, comfort measures, hospice
— Especially before elective surgeries or high-risk procedures
— Document MOLST/POLST in appropriate states
— Hypercapnic encephalopathy may impair decision-making capacity — assess; rely on surrogate decision-makers (spouse, designated proxy)
— Don't assume "DNR = do not treat" — clarify scope (NIV may still be appropriate in DNI patient)
— Medication reconciliation at every transition — inhalers are commonly omitted or duplicated
— Ensure home oxygen and equipment in place before discharge
— Schedule follow-up appointment before discharge (not after)
— Verify patient can afford and access medications — coverage gaps drive readmission
— Provide written action plan and contact information
— Excess oxygen in hypercapnic COPD → worsened CO2 retention (V/Q derangement + Haldane effect); target SpO2 88–92%
— ICS monotherapy in COPD — wrong drug class assignment; pneumonia risk
— Beta-blocker avoidance in COPD + CV disease — leads to undertreatment of heart disease
— Polypharmacy and anticholinergic burden in elderly
— Document exposures; refer for occupational evaluation when warranted
— Assist with Social Security disability documentation (FEV1, exercise capacity)
Step 3 management: A hypercapnic COPD patient with altered mentation on 6 L/min nasal cannula → titrate FiO2 down to target SpO2 88–92%, recheck ABG, prepare for NIV. Excessive O2 is a classic preventable harm.
Board pearl: Always confirm a patient's medication coverage and access before discharge — formulary mismatches drive 30-day readmission rates higher than any single inhaler choice.
Board pearl: The three interventions proven to reduce mortality in COPD are smoking cessation, long-term oxygen (in qualifying hypoxemia), and NIV in acute hypercapnic exacerbation. Pulmonary rehab reduces readmission and mortality after AECOPD.
— 62-year-old smoker (45 pack-years) with chronic dyspnea, productive cough. Pre-BD FEV1/FVC 0.62, FEV1 65%; post-BD 0.64, FEV1 68% predicted. mMRC 2. No exacerbations.
— Answer: GOLD 2, Group B → start LABA + LAMA combination; counsel smoking cessation; vaccinate
— Patient on LABA/LAMA has 2 exacerbations in past year. Eos 380. Next step?
— Answer: Add ICS → triple therapy
— Newly diagnosed COPD with mMRC 1, no exacerbations. Started on fluticasone alone. Best next step?
— Answer: Discontinue ICS monotherapy; start LAMA. ICS not indicated in low-exacerbator without high eos
— Severe dyspnea, pH 7.30, PaCO2 62. Treatment after bronchodilators and steroids?
— Answer: Initiate NIV (BiPAP)
— COPD patient placed on 100% NRB; becomes somnolent. Next step?
— Answer: Titrate FiO2 to SpO2 88–92%; consider NIV if hypercapnic encephalopathy
— 38-year-old nonsmoker with basilar emphysema and elevated LFTs. Next step?
— Answer: Alpha-1 antitrypsin level + phenotype
— Post-MI patient with COPD; physician hesitant to start β-blocker. Recommendation?
— Answer: Start cardioselective β-blocker (metoprolol succinate); benefits outweigh risk
— Patient discharged after AECOPD. When should follow-up be?
— Answer: Within 1–4 weeks; refer to pulmonary rehab within 4 weeks
— Stable COPD, resting SaO2 87% on room air, no cor pulmonale. Recommendation?
— Answer: Initiate LTOT ≥15 hours/day
— 67-year-old new COPD patient, unvaccinated for pneumococcus. Recommendation?
— Answer: PCV20 alone OR PCV15 followed by PPSV23 ≥1 year later
Step 3 management: Recognize the recurring exam logic: diagnosis confirmed by post-BD spirometry → GOLD group assignment → initial therapy → escalate by exacerbations and eosinophils → don't miss mortality-reducing interventions (cessation, LTOT, NIV, rehab, vaccines).
COPD outpatient management hinges on confirming post-bronchodilator FEV1/FVC <0.70, assigning a GOLD ABE group from symptoms and exacerbation history to select inhaler therapy (LAMA, LABA+LAMA, or triple ± ICS guided by eosinophils ≥300), and layering on the mortality-reducing pillars of smoking cessation, vaccinations, LTOT for qualifying hypoxemia, pulmonary rehab, and NIV during hypercapnic exacerbations.
Board pearl: When in doubt on a Step 3 stem, anchor on the three questions: (1) Is the diagnosis spirometrically confirmed? (2) What is the GOLD group (symptoms + exacerbations)? (3) What mortality-reducing intervention is being missed? Most correct answers fall out of those three filters.